Focused On-demand Library for 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.







Alternative names:

Branched-chain alpha-keto acid dehydrogenase E1 component alpha chain

Alternative UPACC:

P12694; B4DP47; E7EW46; Q16034; Q16472


The 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial, also known as the branched-chain alpha-keto acid dehydrogenase E1 component alpha chain, plays a pivotal role in amino acid metabolism. It forms part of the BCKD complex, essential for the oxidative decarboxylation of alpha-ketoacids derived from branched-chain amino acids like valine, leucine, and isoleucine, facilitating energy production.

Therapeutic significance:

Maple syrup urine disease 1A, a metabolic disorder linked to mutations affecting this protein, underscores its critical biological function. The disease manifests with severe neurological symptoms due to the accumulation of branched-chain amino acids. Understanding the protein's role could pave the way for innovative treatments targeting the underlying genetic and metabolic pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.